RECONNECT-PLUS Trial
Cross-source consensus on RECONNECT-PLUS Trial from 1 sources and 5 claims.
1 sources · 5 claims
Other
Other
Other
Other
Highlighted claims
- RECONNECT-PLUS is a four-arm randomized, double-blind, parallel, sham-controlled clinical trial conducted in Madrid. — Long-term effect of transcranial magnetic stimulation and transcranial electrical stimulation in primary progressive aphasia: study protocol for a randomised, double-blind clinical trial (RECONNECT-PLUS)
- Recruitment began on 15 September 2025, with completion planned by January 2028 and final visits by July 2028. — Long-term effect of transcranial magnetic stimulation and transcranial electrical stimulation in primary progressive aphasia: study protocol for a randomised, double-blind clinical trial (RECONNECT-PLUS)
- The trial plans to enroll 80 participants, with 20 participants assigned to each arm. — Long-term effect of transcranial magnetic stimulation and transcranial electrical stimulation in primary progressive aphasia: study protocol for a randomised, double-blind clinical trial (RECONNECT-PLUS)
- Randomization uses fixed blocks of eight and is stratified by PPA variant. — Long-term effect of transcranial magnetic stimulation and transcranial electrical stimulation in primary progressive aphasia: study protocol for a randomised, double-blind clinical trial (RECONNECT-PLUS)
- All four trial arms receive language therapy plus their assigned brain stimulation condition. — Long-term effect of transcranial magnetic stimulation and transcranial electrical stimulation in primary progressive aphasia: study protocol for a randomised, double-blind clinical trial (RECONNECT-PLUS)